Pro‐Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction
暂无分享,去创建一个
K. Anstrom | M. LeWinter | R. Tracy | Jie-Lena Sun | P. Vanburen | J. Steiner | A. Abernethy | Sadi Raza
[1] W. Gaasch. Deliberations on Diastolic Heart Failure. , 2017, The American journal of cardiology.
[2] D. Kass,et al. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap , 2016, Circulation.
[3] R. D. de Boer,et al. Biomarkers in heart failure with preserved ejection fraction , 2016, Netherlands Heart Journal.
[4] A. Gavazzi,et al. Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use , 2015, European journal of heart failure.
[5] M. Pfisterer,et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction , 2015, European journal of heart failure.
[6] V. V. Empel,et al. Inflammation in HFpEF: Key or circumstantial? , 2015 .
[7] R. D. de Boer,et al. State of the Art: Newer biomarkers in heart failure , 2015, European journal of heart failure.
[8] Peter Van Buren,et al. Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction: Contributions of Collagen and Titin , 2015, Circulation.
[9] D. Mann. Innate immunity and the failing heart: the cytokine hypothesis revisited. , 2015, Circulation research.
[10] W. März,et al. C‐reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction , 2014, European journal of heart failure.
[11] J. Dyck,et al. Circulating Levels of Tumor Necrosis Factor-Alpha Receptor 2 Are Increased in Heart Failure with Preserved Ejection Fraction Relative to Heart Failure with Reduced Ejection Fraction: Evidence for a Divergence in Pathophysiology , 2014, PloS one.
[12] Adrian F Hernandez,et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. , 2013, JAMA.
[13] W. Paulus,et al. Biomarkers of heart failure with normal ejection fraction: a systematic review , 2013, European journal of heart failure.
[14] Ilyas Duran,et al. The role of pentraxin 3 as diagnostic value in classification of patients with heart failure. , 2013, Clinical biochemistry.
[15] W. Paulus,et al. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.
[16] D. Mann,et al. Positioning of Inflammatory Biomarkers in the Heart Failure Landscape , 2013, Journal of Cardiovascular Translational Research.
[17] Manesh R. Patel,et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.
[18] A. Mantovani,et al. Long Pentraxin PTX3 Exacerbates Pressure Overload–Induced Left Ventricular Dysfunction , 2013, PloS one.
[19] E. Braunwald,et al. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. , 2012, American heart journal.
[20] Shannon M. Dunlay,et al. Longitudinal Changes in Ejection Fraction in Heart Failure Patients With Preserved and Reduced Ejection Fraction , 2012, Circulation. Heart failure.
[21] D. Maughan,et al. Myosin Cross-Bridge Dynamics in Patients With Hypertension and Concentric Left Ventricular Remodeling , 2012, Circulation. Heart failure.
[22] L. Tavazzi,et al. Pentraxin‐3 in chronic heart failure: the CORONA and GISSI‐HF trials , 2012, European journal of heart failure.
[23] J. Bronzwaer,et al. Low Myocardial Protein Kinase G Activity in Heart Failure With Preserved Ejection Fraction , 2012, Circulation.
[24] T. Kodama,et al. Pentraxin 3: A Novel Biomarker for Inflammatory Cardiovascular Disease , 2012, International journal of vascular medicine.
[25] H. Ogawa,et al. Pentraxin 3 Is a New Inflammatory Marker Correlated With Left Ventricular Diastolic Dysfunction and Heart Failure With Normal Ejection Fraction , 2011 .
[26] J. McMurray,et al. Neurohormonal Activation in Acute Heart Failure: Results from VERITAS , 2011, Cardiology.
[27] R. McKelvie,et al. Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction: Results of the I-PRESERVE Collagen Substudy , 2011, Circulation. Heart failure.
[28] M. LeWinter,et al. Tachycardia-induced diastolic dysfunction and resting tone in myocardium from patients with a normal ejection fraction. , 2011, Journal of the American College of Cardiology.
[29] Adrian F Hernandez,et al. Diuretic strategies in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.
[30] W. Paulus,et al. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. , 2011, European heart journal.
[31] C. Tschöpe,et al. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. , 2011, Journal of the American College of Cardiology.
[32] P. Steendijk,et al. Cardiac Inflammation Contributes to Changes in the Extracellular Matrix in Patients With Heart Failure and Normal Ejection Fraction , 2011, Circulation. Heart failure.
[33] Hans L Hillege,et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction , 2010, Annals of medicine.
[34] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[35] L. Kuller,et al. Associations of Pentraxin 3 With Cardiovascular Disease and All-Cause Death: The Cardiovascular Health Study , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[36] G. Novo,et al. Biomarkers in heart failure. , 2009, Frontiers in bioscience.
[37] K. Node,et al. Prognostic value of pentraxin 3 in patients with chronic heart failure. , 2008, International journal of cardiology.
[38] J. Killian,et al. Tumor Necrosis Factor-&agr; and Mortality in Heart Failure: A Community Study , 2008, Circulation.
[39] I. Kubota,et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. , 2007, American heart journal.
[40] J. Fleg,et al. Heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.
[41] J. Polak,et al. C-Reactive Protein and the 10-Year Incidence of Coronary Heart Disease in Older Men and Women , 2005 .
[42] J. Cohn,et al. C-Reactive Protein in Heart Failure: Prognostic Value and the Effect of Valsartan , 2005, Circulation.
[43] J. Polak,et al. C-Reactive Protein and the 10-Year Incidence of Coronary Heart Disease in Older Men and Women: The Cardiovascular Health Study , 2005, Circulation.
[44] A. Hoeft,et al. [Cytokines and heart failure]. , 2004, Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS.
[45] S. Rubin,et al. Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). , 2003, The American journal of cardiology.
[46] D. Mann,et al. Angiotensin II Induces Tumor Necrosis Factor Biosynthesis in the Adult Mammalian Heart Through a Protein Kinase C-Dependent Pathway , 2002, Circulation.
[47] Anita Deswal,et al. Cytokines and Cytokine Receptors in Advanced Heart Failure: An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST) , 2001, Circulation.
[48] S. Anker,et al. Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure , 2000, Circulation.
[49] J. Thomas,et al. Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. , 2000, Journal of the American College of Cardiology.
[50] B. Chandrasekar,et al. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. , 2000, Circulation.
[51] F. Clubb,et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. , 1998, Circulation.
[52] J. Kjekshus,et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. , 1998, Circulation.
[53] H. Oral,et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.
[54] D. Mann,et al. Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .
[55] D. Mann,et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. , 1996, Circulation.
[56] H. Fillit,et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.